Taxifolin (also known as dihydroquercetin) is a flavonoid found in various plants, and it has been investigated for potential cardiovascular benefits, including the management or prevention of arteriosclerosis (the thickening or hardening of the arteries). Scientific interest in taxifolin comes from its demonstrated antioxidant, anti-inflammatory, and lipid-lowering properties in preclinical studies.

In animal models, taxifolin has shown efficacy in reducing oxidative stress and inflammation—two key contributors to the pathogenesis of arteriosclerosis. Some studies report that taxifolin can decrease serum lipid levels, inhibit LDL oxidation, and protect endothelial function, all of which are relevant to the development of arteriosclerotic changes. For example, a study in Biomedicine & Pharmacotherapy (2017) found that taxifolin supplementation in rats reduced atherosclerotic plaque formation and improved lipid profiles.

However, clinical evidence in humans remains limited. There are very few controlled trials directly evaluating taxifolin for arteriosclerosis in humans, and most available data are from animal or in vitro studies. While the molecule is included in some dietary supplements targeting cardiovascular health, its use for arteriosclerosis is not yet strongly validated by robust human clinical research.

In summary, scientific rationale exists based on preclinical research, but the overall evidence is still preliminary, meriting a moderate rating (2 out of 5) until further human studies are conducted.